ASCO Advance of the Year: Immunotherapy 2.0 – Cancer Therapy Advisor
|
ASCO Advance of the Year: Immunotherapy 2.0
Cancer Therapy Advisor The American Society of Clinical Oncology (ASCO) named immunotherapy the “advance of the year” for the second year in a row, recognizing the expanding use of these agents, according to Clinical Cancer Advances 2017: ASCO's Annual Report on … |
